Delivery Order SPE2DB20D3101-SPE2DB24FRTS6

Award Date 9/3/24
Potential Completion Date 9/4/24
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of 4,563,337,505 units of Ondansetron HCL 4 mg tablets to the Defense Logistics Agency (DLA). The $3,198.52 firm fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on January 16, 2024 with a completion date of January 17, 2024. The contract is a delivery order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This...
This federal contract award is for the delivery of ondansetron hydrochloride 4 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $16,994.84, was awarded on November 22, 2024 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed price pricing type and a completion date of November 25, 2024. The contract is a delivery order and was not set aside for any specific business type. AmerisourceBergen...
This federal contract award is for the delivery of 4 mg ondansetron hydrochloride tablets to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distribution company that holds a single-award Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products and...
This federal contract award is for the delivery of 4,566,165,480 units of ondansetron HCL 4 mg tablets to the Defense Logistics Agency (DLA). The firm-fixed-price delivery order, valued at $22,056.48, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 21, 2024, with a completion date of October 22, 2024. The contract is not set aside for any specific business type. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award is for the delivery of Ondansetron HCL 4 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The $32,573.01 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on September 16, 2024. The contract has an ultimate completion date of September 17, 2024 and is not set aside for any specific business type. This order is likely part of a larger Indefinite Delivery Contract (IDC) between...
This federal contract award is for the delivery of 4,567,227,090 units of 4 mg Ondansetron HCL tablets to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The $2,294.40 firm-fixed-price delivery order contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on February 11, 2025, with a completion date of February 12, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite...
This federal contract award is for the delivery of Ondansetron HCL 4 mg tablets (30s) to the Defense Logistics Agency (DLA). The $1,459.12 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, under an indefinite delivery contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999. The IDC serves as the primary vehicle for Amerisourcebergen to provide a wide range of pharmaceutical and medical supplies to support...
This federal contract award is for the delivery of Ondansetron HCL 4 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $7,640.03, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on March 12, 2024, with a completion date of March 13, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to...
This federal contract award is for the delivery of 4,564,662,850 units of Ondansetron ODT 4 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The $5,905.15 fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on May 20, 2024, with a completion date of May 21, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award is for the delivery of Ondansetron HCL 4 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on March 13, 2025 with a ceiling value of $1,285.54 and a completion date of March 14, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB24FRTS6
    Delivery Order

This federal contract award is for the delivery of ondansetron hydrochloride 4 mg tablets to the Defense Logistics Agency (DLA) on a firm fixed-price basis. The contract, valued at $1,386.02, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, with an ultimate completion date of September 4, 2024. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 10:19 AM